Are minoxidil and hydralazine (antihypertensive medications) from the same pharmacological class?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

No, minoxidil and hydralazine are not from the same medication class, though they share some similarities as both are classified under direct vasodilators. According to the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults 1, minoxidil and hydralazine are both listed under the class of direct vasodilators, but they work through different mechanisms. Minoxidil opens potassium channels in vascular smooth muscle cells, leading to hyperpolarization and vasodilation, while hydralazine causes vasodilation by interfering with calcium movement in vascular smooth muscle and may involve nitric oxide pathways.

Some key points to consider:

  • Both minoxidil and hydralazine are used to manage hypertension, but they have different primary uses today, with minoxidil being primarily used topically for hair loss treatment (as Rogaine) and hydralazine remaining in use for managing hypertension, particularly in pregnancy-related hypertension and heart failure.
  • The side effect profiles of these medications also differ, with oral minoxidil causing hypertrichosis (excessive hair growth) and hydralazine potentially causing a lupus-like syndrome with long-term use, as noted in the guideline 1.
  • The dosages and frequencies of these medications can vary, with hydralazine typically given at 100-200 mg/day, 2 or 3 times daily, and minoxidil given at 5-100 mg/day, 1-3 times daily, according to the guideline 1.
  • It's also important to consider the potential interactions and contraindications of these medications, such as the need to use hydralazine with a diuretic and beta blocker to avoid sodium and water retention and reflex tachycardia, as mentioned in the guideline 1.

Overall, while minoxidil and hydralazine share some similarities, they are distinct medications with different mechanisms of action, uses, and side effect profiles, as supported by the guideline 1.

From the Research

Pharmacological Classification of Minoxidil and Hydralazine

  • Minoxidil and hydralazine are both used as antihypertensive medications, but their pharmacological classification is not explicitly stated as the same in the provided studies.
  • According to 2, vasodilatory agents are divided into 9 classes, and minoxidil is classified as a potassium channel opener, while hydralazine is mentioned as a drug used to treat severe hypertensive emergencies, but its specific class is not stated.
  • However, 3 mentions that minoxidil and hydralazine are related in chemical structure, suggesting some similarity between the two drugs.

Mechanism of Action

  • The mechanism of action of minoxidil and hydralazine is not fully understood, but they are both known to have a direct vasodilator action, lowering total peripheral resistance and blood pressure 4, 3.
  • 3 suggests that the antihypertensive action of minoxidil and hydralazine may not be related to a direct depressant action on vascular smooth muscle function, and it is possible that they lower blood pressure by different mechanisms.

Clinical Use

  • Minoxidil is generally reserved for patients with severe hypertension that is refractory to other treatment 5, 2.
  • Hydralazine is used to treat severe hypertensive emergencies, primary pulmonary and malignant hypertension, and in severe preeclampsia 2.
  • Both minoxidil and hydralazine can cause vasodilatory edema, a common side effect of antihypertensive therapy with vasodilators 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clinical pharmacokinetics of vasodilators. Part I.

Clinical pharmacokinetics, 1998

Research

Vasodilators in the treatment of hypertension.

Comprehensive therapy, 1982

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.